Research Impact Alternative
Staff in the School of Pharmacy publish world-class research which has local and global impact.
Reseach in the school is organised around five interdisciplinary research themes, the impact of which can be seen demonstrated in the case studies below.
Professor Lorraine Martin leads the team at Queen’s in what is a highly ambitious, collaborative research partnership that is harnessing complementary resources & expertise from the School of Pharmacy
BREATH is a cross-border €7.7m project funded by the EU’s INTERREG VA Programme, which is managed by the Special EU Programmes Body (SEUPB). Throughout this five-year project, over 30 researchers and doctoral students will work together not only to better understand COPD but to raise awareness of the disease to help encourage preventative measures, timely treatment and disease management
QUB has been at the forefront of global efforts to develop products to protect women against sexually transmitted infection with human immunodeficiency virus (HIV).
Supported by extensive research by Professor Karl Malcolm & Dr Peter Boyd over 17 years (including early development of the concept), a vaginal ring device offering sustained release of the antiretroviral drug dapivirine (Figure 1) has greatly impacted the direction and technology within the HIV prevention field. Phase 3 clinical trials were successfully completed in 2016, and a positive opinion from the European Medicines Agency was announced in July 2020.
ProAxsis Ltd. was founded by Professor Lorraine Martin (CEO) and Professor Brian Walker (CSO) in 2013 as a spin-out from the School of Pharmacy, QUB and is an excellent example of a programme of work
The company develops novel biomarker assays utilising a patented ProteaseTag® technology which allows for the measurement of active proteases in chronic diseases, in the first instance chronic airways diseases. Outputs to date include two patents, multiple conference presentations and a high impact publication in AJRCCM which reports the first use and validation of the first commercial product in the chronic airways disease, bronchiectasis.
Digital dermatitis occurs extensively in cattle population, with 70-95% of dairy herds showing symptoms and herd prevalence rates averaging between 20-30% in Europe and the USA.
In the UK, at least 70% of herds are affected among which about 41% cattle have lesions. QUB research has led to the development of a suite of efficacious treatments that are now sold in three continents, with sales of more than GBP10,000,000 to date. Sales revenue has allowed the company to expand, building a second plant and which has been successfully audited by FDA and the only facility permitted outside the US to manufacture this range of products. The expansion has also allowed the company to employ 6 new staff.